13 completed, 2 unknown, 2 withdrawn, 1 terminated. 10 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 1 | 6 | Completed 4, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
Follow Chronic Hepatitis C Virus Infection: new trials by email Literature Review of Chronic Hepatitis C Virus Infection trials Research Report on Chronic Hepatitis C Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients SOF plus (OBV/PTV/r) plus RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 113 | 2017-03-01 | 2020-05-18 |
| ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants SOF/SMV/DCV/RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 94 | 2017-03-01 | 2020-05-14 |
| Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 (SOF and DCV), (SOF, DCV, and RBV) - Chronic Hepatitis C Virus Infection | Phase 2 / Phase 3 | Completed | Beni-Suef University | 946 | 2016-04-01 | 2020-05-15 |
| Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection P1101 + Ribavirin, PEG-Intron + Ribavirin - Chronic Hepatitis C Virus Infection | Phase 3 | Completed | PharmaEssentia | 222 | 2016-01-12 | 2022-01-18 |
| Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Sofosbuvir + Simeprevir + Ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | Beni-Suef University | 203 | 2015-04-01 | 2020-05-12 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection OBV/PTV/r, Sofosbuvir, Ribavirin (RBV) - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie | 70 | 2014-12-19 | 2021-07-12 |
| Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors Chronic Hepatitis C Virus Infection | Withdrawn | Intermountain Health Care, Inc. | 2013-05-01 | 2018-03-22 | ||
| Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction BMS-914143 (Peginterferon Lambda-1a) - Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection | Phase 1 | Completed | Bristol-Myers Squibb | 43 | 2012-09-01 | 2013-06-05 |
| A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 152 | 2010-08-01 | 2020-09-30 |
| A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Interferon α-5, Interferon-α5 plus Interferon-α 2b, Interferon α-2b (INTRON® A) - Chronic Hepatitis C Virus Infection, Genotype 1 | Phase 1 / Phase 2 | Completed | Digna Biotech S.L. | 70 | 2010-05-01 | 2013-02-05 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ABT-333, Placebo for ABT-333, Pegylated interferon - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 30 | 2009-03-01 | 2018-07-02 |
| FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy No intervention - Chronic Hepatitis C Virus Infection | Completed | University Health Network, Toronto | 54 | 2008-02-01 | 2013-07-25 | |
| Study of CTS-1027 in Hepatitis C Patients CTS-1027, Placebo - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | Conatus Pharmaceuticals Inc. | 87 | 2007-12-01 | 2010-09-16 |
| Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients CHRONVAC-C® - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Unknown | Tripep AB | 12 | 2007-10-01 | 2010-02-10 |
| Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers XTL-2125 - Chronic Hepatitis C Virus Infection | Phase 1 | Withdrawn | Hadassah Medical Organization | 60 | 2006-02-01 | 2007-11-06 |
| Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT Chronic Hepatitis C Virus Infection | Unknown | Hadassah Medical Organization | 500 | 2006-02-01 | 2006-02-22 | |
| sgp130 in Chronic Human Liver Disease Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection | Completed | Erasme University Hospital | 129 | 2005-01-01 | 2008-10-09 | |
| PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy PEGIntron plus ribavirin - Chronic Hepatitis C Virus Infection | Phase 3 | Completed | Hepatitis Resource Network | 600 | 2005-09-22 |
Fibrosis (1) · Hepatitis B, Chronic (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Liver Diseases, Alcoholic (1) · Recurrence (1)
Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Digestive System Diseases (3) · Disease Attributes (3) · Liver Diseases (3) · Blood-Borne Infections (2) · Chronic Disease (2) · Communicable Diseases (2) · Hepatitis (2) · Hepatitis, Chronic (2) · Hepatitis, Viral, Human (2) · Infections (2) · Virus Diseases (2) · Alcohol-Induced Disorders (1) · Alcohol-Related Disorders (1)
Ribavirin (7) · Sofosbuvir (2) · ombitasvir (2) · paritaprevir (2) · peginterferon alfa-2b (2) · Introns (1) · Ritonavir (1) · Simeprevir (1) · daclatasvir (1) · dasabuvir (1) · lomibuvir (1) · peginterferon alfa-2a (1) · peginterferon lambda-1a (1) · telaprevir (1)
Beni-Suef University (4) · Hadassah Medical Organization (2) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Bristol-Myers Squibb (1) · Conatus Pharmaceuticals Inc. (1) · Digna Biotech S.L. (1) · Erasme University Hospital (1) · Hepatitis Resource Network (1) · Intermountain Health Care, Inc. (1) · PharmaEssentia (1) · Tripep AB (1) · University Health Network, Toronto (1) · Vertex Pharmaceuticals Incorporated (1)
United States (6) · Egypt (2) · Israel (2) · Belgium (1) · Canada (1) · China (1) · New Zealand (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1)
Anders Vahlne, Professor (1) · Arnaud Lemmers, MD (1) · Daniel Cohen, MD (1) · Eithan Galun, MD (1) · Gadi Lalazar, MD (1) · Gary Levy, MD (1) · Mariem Charafeddine, MD (1) · Mark Sulkowski, MD (1) · Mohammed Abdel-Gabbar, Ass. Prof (1) · Ola RH Weiland, Professor (1) · Shlomo Dagan, PhD (1)
PMID 12601348, PMID 16702586, PMID 19196737, PMID 20198626, PMID 21851142, PMID 22895429, PMID 23034845, PMID 23183613, PMID 23437439, PMID 24901821, PMID 24982088, PMID 26596948, PMID 29546644, PMID 29625827, PMID 29754329, PMID 30598598
2009 (1), 2014 (1)